iShares US Pharmaceuticals ETF
86 hedge funds and large institutions have $247M invested in iShares US Pharmaceuticals ETF in 2014 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 4 closing their positions.
273% more capital inflows, than outflows
Capital inflows: $41.1M | Capital outflows: $11M
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
13% more funds holding
Funds holding: 76 → 86 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Braver Wealth Management
Needham,
Massachusetts
|
+$6.38M |
| 2 |
Stringer Asset Management
Memphis,
Tennessee
|
+$5.56M |
| 3 |
Tower Research Capital (TRC)
New York
|
+$4.19M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$3.61M |
| 5 |
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
+$2.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DRW Securities
Chicago,
Illinois
|
-$2.74M |
| 2 |
Pinnacle Advisory Group
Columbia,
Maryland
|
-$1.99M |
| 3 |
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$1.7M |
| 4 |
Virtu KCG Holdings
New York
|
-$1.48M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.23M |
IHE Hedge Fund Activity: Q1 2014 in Review
86 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2014, worth a combined $247M — up 22% from $202M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IHE positions and 4 closed out — a net gain of 10 holders — while 35 added to existing stakes and 21 trimmed.
The largest buyer was Braver Wealth Management, opening a new position worth an estimated $6.38M. The largest seller was DRW Securities, exiting entirely with an estimated $2.74M sold.
- 86 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2014, up from 76 in Q4 2013.
- Funds reported $247M of iShares US Pharmaceuticals ETF stock for Q1 2014, up 22% quarter-over-quarter.
- 14 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2014 and 4 closed out, a net change of +10 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2014 was Braver Wealth Management, an estimated $6.38M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2014 was DRW Securities, an estimated $2.74M sold.
Based on aggregated 13F filings for Q1 2014.